ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PLX Protalix BioTherapeutics Inc

1.14
-0.03 (-2.56%)
After Hours
Last Updated: 22:05:06
Delayed by 15 minutes
Share Name Share Symbol Market Type
Protalix BioTherapeutics Inc AMEX:PLX AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.03 -2.56% 1.14 1.16 1.13 1.16 189,203 22:05:06

Additional Proxy Soliciting Materials (definitive) (defa14a)

28/06/2023 9:30pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 

Filed by the Registrant  x

 

Filed by a Party other than the Registrant  ¨

 

Check the appropriate box:

 

¨Preliminary Proxy Statement

 

¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

¨Definitive Proxy Statement

 

xDefinitive Additional Materials

 

¨Soliciting Material Pursuant to §240.14a-12

 

Protalix BioTherapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

xNo fee required.

 

¨Fee paid previously with preliminary materials.

 

¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

 

 

 

 

 

 

 

 

  Barcode  
  Shareholder Name  
  Address 1  
  Address 2  
  Address 3  

 

 

Protalix Biotherapeutics Announces Adjournment of Annual Meeting of Stockholders

 

Protalix Biotherapeutics. (Ticker: PLX) recently announced that the June 28th, 2023, Annual Meeting is being adjourned until July 13th, 2023, to provide stockholders with additional time to vote on Proposal 5, approval of an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of Common Stock.

 

Our records indicate your account is currently unvoted.

 

The Board of Directors as well as leading professional advisory firms ISS and Glass Lewis recommend you FOR Proposal 5.

 

Proposal 5 requires an affirmative vote of 50% of the outstanding shares for passage. By not responding with your vote, you are essentially opposing this proposal. Therefore, we urge our stockholders who have not yet executed their vote to please do so. This will help save on further solicitation costs and ensure that your important vote is represented.

 

Please vote your shares of stock now so that your vote can be counted without delay. If you have any questions or require assistance in voting your shares, please contact our proxy solicitor Alliance Advisors toll-free at +1 (855) 200- 7892 or email PLX@AllianceAdvisors.com.

 

If you wish to vote electronically online you can scan the QR code below:

 

 

Insert QR CODE HERE

 

 

Sincerely,

 

Gina Balderas

Operations Manager

 

 

IF YOU HAVE RECENTLY VOTED PLEASE ACCEPT OUR THANKS AND DISREGARD THIS REQUEST.

 

 

 

 

1 Year Protalix BioTherapeutics Chart

1 Year Protalix BioTherapeutics Chart

1 Month Protalix BioTherapeutics Chart

1 Month Protalix BioTherapeutics Chart